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Sumnlary 
Chronic granulomatous disease  (CGD) is characterized by the failure of phagocytic leukocytes 
to generate superoxide, needed for the intracellular killing of microorganisms. This is caused by 
mutations in any one of the four subunits of the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase. In a rare, autosomal recessive form ofCGD, a 67-kD cytosolic component 
of this enzyme (p67-phox) is missing. We here report on a patient with a mutation in the p67- 
phox gene that leads to expression of a nonfunctional p67-phox protein. The purified granulo- 
cytes  of this  patient  failed  to  produce  superoxide  and  contained  about  half of the  normal 
amount ofp67-phox.  Analysis of the cDNA and genomic DNA of this patient showed that the 
patient is a compound heterozygote for a triplet nucleotide deletion in the p67-phox gene, pre- 
dicting an in-frame deletion oflysine 58 in the p67-phox protein and a larger deletion of 11-13 
kb in the other allele.  Interestingly, the S8Lys deletion in p67-phox disrupts the interaction with 
p21-rac1, a ras-related protein involved in the activation of the NADPH oxidase. In contrast to 
normal  neutrophils,  in  which  p47-phox  and  p67-phox  translocate  to  the  plasma membrane 
upon cell activation, the cells of the patient did not show this translocation, indicating that an 
interaction between p67-phox and p21-racl  is essential for translocation of these cytosolic pro- 
teins and activation of the NADPH oxidase. Moreover, this CGD patient represents the first 
case of a disease  caused by a disturbed binding of a ras-related protein to its target protein. 
p hagocytic  leukocytes  use  reactive  oxygen  metabolites 
to  kill  ingested  microorganisms.  The  first  step  in  the 
production of these compounds is the generation of super- 
oxide by the nicotinamide adenine dinucleotide phosphate 
(NADPH) 1 oxidase  enzyme  in  these  cells.  This  enzyme 
consists of a flavocytochrome (cytochrome bs_ss), located in 
the  plasma  membrane  (1),  and  several  cytosolic  compo- 
nents that translocate to the plasma membrane upon activa- 
tion of the oxidase (2, 3).  This activation is initiated by at- 
1Abbreviations used in this  paper: CGD, chronic granulomatous disease; FAD, 
flavin adenine dinucleotide; GST, glutathione-S-transferase; NADPH, 
nicotinamide adenine dinucleotide phosphate; PAF. platelet-activating 
factor; SOl), superoxide dismutase; STZ, serum-treated  zymosan. 
tachment  of  opsonized  microorganisms  to  cell  surface 
receptors and serves to restrict the generation of the reac- 
tive oxygen compounds to periods ofphagocytosis. During 
activation,  the  47- and the  67-kD  cytosolic oxidase com- 
ponents  (called p47-phox and p67-phox,  respectively) cou- 
ple to the flavocytochrome and probably induce a confor- 
mational  change  in  this  protein  that  renders  its  flavin 
accessible to NADPH  (4).  As a result,  electrons flow from 
NADPH via flavin adenine dinucleotide  (FAD) and heme 
to oxygen, thus generating superoxide. 
Mutations  in  either  the  ix  or  the  13  subunit  of cyto- 
chrome bss  8 in p47-phox or in p67-phox lead to a dysfunc- 
tion  of the  NADPH  oxidase  enzyme  (5).  Patients  with 
such mutations suffer from chronic  granulomatous disease 
(CGD), characterized by severe recurrent infections.  There 
1243  J. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/96/10/1243/07  $2.00 
Volmne 184  October 1996 1243-1249 are at least two  other proteins thus far described to be in- 
volved  in  the  NADPH  oxidase:  p40-phox,  which  was 
shown to reside in a complex with p67-phox in the cytosol 
of resting neutrophils (6, 7), and the small GTPase p21-racl 
or p21-rac2  (8,  9).  This latter protein,  unlike p40-phox,  is 
essential for the activity of the NADPH  oxidase (10,  11). 
The most common form of CGD  ('--'60% of cases) is X 
linked and caused by mutations in the CYBB  gene encod- 
ing the  cytochrome  b.sss [3 subunit  (12).  Mutations  in  the 
CYBA  gene  encoding  the  tx  subunit  of the  cytochrome 
lead to a rare, autosomal form of the disease, found in "~ 
of patients (13).  The 47-kD  component is encoded by the 
NCFI  gene;  mutations  in  this gene  lead to  the  common 
autosomal-recessive type of CGD,  with an estimated inci- 
dence of 30% (14,  15). Finally, another rare autosomal type 
of CGD is caused by mutations in the NCF2 gene, encod- 
ing p67-phox  (16).  This type of CGD  is called A67  CGD 
and  is found  in  <5%  of patients.  So  far,  all reported A67 
CGD  patients  completely  lack  material  immunoreactive 
with  antibodies directed against p67-phox.  Only  three  of 
these  patients  have  been  characterized  at  the  molecular 
level  (17-19).  All three  patients  appeared to  be  homozy- 
gous for a mutation in the NCF2 gene. We here report on 
two  hetereozygous  mutations  in  an  additional p67-phox- 
affected CGD patient. Interestingly, one of these mutations 
apparently leads to the expression of a nonfunctional p67- 
phox  protein.  Since p67-phox  has  been  shown  to  interact 
with p21-rac1  (20), we investigated the effect of this muta- 
tion on this interaction and found it to be impaired. 
Clinical History 
A  girl, born in 1976 in Chile to parents of South Ameri- 
can  origin,  was  adopted  by  Swedish  parents  in  1977.  A 
medical examination  at  arrival in  Sweden  revealed only a 
calcified lymph gland in the left axillae. At age 2, she had a 
left-sided lobar pneumonia.  In  1980,  an abscess in her pa- 
rotid gland revealed growth of Pseudomonas cepacia. At age 7, 
she had an abscess in her left axillae, but cultures were neg- 
ative.  Histologic examination showed  unspecific necrotiz- 
ing inflammation without granuloma formation.  The same 
year she developed sterile pyuria. At age 9,  she developed 
synovitis at the distal tibial bone.  The  possibility of tuber- 
culosis  was  considered;  however,  tuberculosis  cultures  as 
well as regular cultures were  negative. A  biospy from  the 
tibial bone  revealed osteitis but  no  granuloma.  The  same 
year, granulocyte function tests showed no increase in oxi- 
dative metabolism. Thus,  the diagnosis of CGD  was estab- 
lished. She was treated with rifampicin and trimethoprim- 
sulphamethoxazole  for  her  osteitis and  was  thereafter put 
on  prophylactic  treatment  with  trimethoprim-sulpha- 
methoxazole.  The  symptoms  in  her  joints  disappeared 
gradually, and there are no sequalae visible on x-ray photo- 
graphs.  During the years 1986-1990  she suffered from  re- 
peated lymphadenitis and  a  swelling of the  parotid gland, 
despite  antibiotic  prophylaxis.  She  was  also  treated  for  a 
Salmotwlla septicenfia. Since  1990,  she has been well with- 
out antibiotic prophylaxis. 
Materials  and Methods 
Purification of Granulocytes.  Blood was  drawn m  venoject cit- 
rate tubes (Terumo Europe, Leuwen, Belgium), and gTauulocytes 
were purified as described previously (21). The cells (>90% neu- 
trophils and  2-10%  eosinophils) were  suspended in  incubation 
medium (I32 mM NaC1,  6 mM KC1, 1.2 mM Na2HPO4,  1 mM 
CaC12,  1 mM MgC12, 20 mM Hepes,  5 mM glucose, and t).5% 
(wt/vol) human serum albumin (pH 7.4). 
Fuftctional Tests.  The  nitro blue tetrazdmm  (NBT)  slide test 
was  performed  as  described  previously  (22).  About  400  cells 
stained with nuclear fast red were examined and scored as forma- 
zan negative or positive. 
NADPH oxidase activity was also measured in the cell-fi-ee ac- 
tivation system  as  previously described  (23).  In  short,  purified 
plasma membranes from sonicated granulocytes (I0  I~g of pro- 
tein) and cytosol from sonicated granulocytes (120 I.tg of protein) 
were incubated at 28~  in 800 I-tl ofoxidase buffer (pH 7.2) con- 
taining 75  mM  NaCI, 20 mM  Hepes,  170  mM  sucrose,  1 mM 
MgC12, (i).5 mM EGTA, and 60 ~M ferricytochrome c. The as- 
sembly of oxidase components was started by the addition of SI)S 
(100  I~M).  NADPH  (250  IxM)  was  added  after  3  nfin,  and 
NADPH oxidase activity was measured by the slope of the absor- 
bance change at 550 nm. 
H/estern Blotting.  The  presence of NADPH  oxidase colnpo- 
nents was determined on Western blots with antisera specific tbr 
the cytosolic components as described (23). 
Preparation of RNA and DNA.  P,  NA was isolated from mono- 
nuclear leukocytes as described previously (17).  Genomic DNA 
was isolated from circulating leukocytes (24). 
Northern Blottilg.  P,.NA corresponding to  10 v monocytes (11) 
~g) was submitted to electrophoresis in 1.2% (wt/voI) agarose gels 
in  the  presence  of formaldehyde and  was  blotted  onto  Gene- 
screen Plus membrane filters (NEN-l)upont, Boston, MA). Blots 
were hybridized with a p67-phox cl)NA probe containing the to- 
tal coding region and labeled by random priming. 
Southern Blotting.  Analysis ofgenonfic 1)NA by Southern blot 
was performed after treatment with EcoRI or HindlIl essentially 
as described (25). For hybridization, a full-length p67-pbox cl)NA 
was used (17). 
Amplication and Sequencing qf DNA.  For analysis ofmRNA se- 
quences,  first-strand cDNA  was  synthesized  from  t<NA.  The 
p67-phox  cDNA  coding  region  was  amplified by  PCR  in  six 
overlapping fragments as described by (17).  The sequence of the 
oligonucleotide primers used for this PCR  are also given refer- 
ence  17.  The  PCIL product was  purified with the Geneclean  I1 
kit (BIO 1(/1, Inc., Vista, CA) to remove the primers and nucle- 
otides. 20/) ng of the purified I)NA samples was annealed with 40 
ng  of one  of the  printers  used  for  amplification by first  being 
heated tbr 3 min at 100~  and then being chilled on ice water in 
the presence of 10% DMSO.  Direct sequence analysis was  per- 
formed with  the  sequenase  version 2.0  kit  (United States  Bio- 
chemical Corp., Cleveland, OH).  In genomic I)NA, the muta- 
tions were identified in a similar way. 
Analysis of p21-racl Bindi,g to Ghctatllione-S-Tr,m.!'fi!rase (GS'I) 
Fusion ProteiHs.  To introduce the deletion of amino acid 58  in 
p67-phox we used a wild-type p67-pllox construct in pGEX-2T 
(Pharmacia, Uppsala, Sweden) as a template in a PCR. with oligo- 
nucleotide  primers  5'-CTGGTAAAGGCCTCTGCTTCAGTC- 
ATGTTCTTC-3'  (sense)  and  5'-GATGAATTCTAATCA- 
TGTCCCTGGTGG-3'  (antisense).  The  product  was  digested 
with  Stul  and  EcoRl  (underlined nucleotides) and ligated into 
the Stul/Ecol-ZI-digested pGEX-p67tvt  plasmid. The  introduced 
deletion was confirmed by sequencing. Expression of GST fusion 
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and patients after informed consent had been obtained, and granulocytes 
were purified and fractionated as described previously (28, 32). Granulo- 
cyte cytosol (20 ptg of  protein) from either healthy donors (con  I and con2), 
from the patient (A67)  or from a classical p67-phox-deficient patient 
(A67  ~  were separated on a  10% polyacrylanfide gel and subsequently 
blotted onto  nitrocellulose. Staining with polyclonal antibodies against 
the  COOH-terminal  regions of these proteins revealed a  diminished 
amount of p67-phox in the patient's granulocytes. 
proteins was performed in Escherichia coli DH5(x as previously de- 
scribed  (26). Protein  expression  was  compared  by  gel  electro- 
phoresis and protein staining. We found that the mutated p67-phox 
was poorly expressed; ~10-fold less than wild-type  p67-ph0x. GST 
alone,  GST-p47-phox, GST-p67-phox, or GST-p67-phoxASULys 
were  spotted  onto  nitrocellulose.  The  blot was  then  incubated 
with  [32p]~xGTP-loaded p21-rac1 as described  (27). Binding was 
visualized  by subsequent exposure of the blot to hyperfihn-ECL 
(Amersham Corp., Arlington Heights, IL) for t  h. 
Tra,slocation of p47-phox and p67-phox in  Intact Granulocytes. 
Cells  were stinmlated  with  PMA  (100  ng/ml)  or serum-treated 
zymosan (STZ; 1 mg/ml) for 7 rain and fractionated as described 
(24). Subsequently,  supernatants  and plasma membranes were im- 
munoblotted as described  (28). 
TratMocation of p47-phox and p67-phox in the Cell-free System. 
1 txg GST-p47-phox, 1 txg GST-p67-phox, and a fraction contain- 
ing p21-rac (obtained from 240 txg ofcytosolic protein) (29) were 
mixed  with  plasma  membranes  (40  txg). After  activation  with 
SDS and GTP'yS and centrifugation  over sucrose gradients, plasma 
membranes  were  collected  as  described  (24).  One-fifth  of the 
membrane  fractions  was  assayed for superoxide production, and 
the remainder was TCA precipitated  and processed  for Western 
blotting. 
Results  and Discussion 
Identification of CGD Type.  The  patient  was  identified 
as a  CGD patient  by lack of superoxide  generation by her 
purified granulocytes after activation with PMA in the NBT 
slide  test.  Likewise,  her cells did not show any superoxide 
dismutase  (SOD)-sensitive  cytochrome  c  reduction  with 
several other stimuli tested  (fMLP,  STZ,  platelet-activating 
factor  [PAF]),  indicating  a  total  lack  of NADPH  oxidase 
activity.  In  the  cell-free  activation  system,  the  cytosol  of 
the patient's granulocytes showed only 3% of normal activ- 
ity, whereas the membranes of these cells  had normal activ- 
ity. The cytosolic activity of the patient's cells  was fully re- 
stored  by addition  of recombinant  p67-phox  protein,  but 
not  by  addition  of recombinant  p47-phox.  On  Western 
blots, p47-phox was clearly present in the cytosol of the pa- 
tient's resting granulocytes, but p67-phox was also detected, 
albeit  at  a  lower level  (Fig.  1).  Densitometric  scanning  of 
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the blots showed 46  +  9% (mean +  SD, n  =  3) of the nor- 
mal amount ofp67-phox.  Thus, the patient suffers from the 
autosomal form of CGD leading to subnormal amounts of 
p67-phox,  also called the A67 + CGD subtype. 
Identification of the Mutations  On Northern blot, the size 
and the amount ofp67-phox mRNA  of the patient was ap- 
parently normal (not shown). The p67-phox mP,  NA of the 
patient was converted to cDNA and amplified in six over- 
lapping  fragments.  Electrophoresis  on  agarose  gel  showed 
that  the  amplified  fragments  from  the  patient  had  a  size 
similar  to  that  of fragments  obtained  from normal  control 
cells.  Direct  sequencing  of the  first  fragment  with  primer 
67-109  (17)  revealed a triplet  nucleotide deletion between 
position  170  and  174,  predicting  deletion  of a  lysine  at 
amino acid position 58. This mutation appeared to be con- 
fined  to  one  allele,  because  the  normal  sequence  was  also 
detectable,  albeit faintly.  Therefore, we amplified genomic 
DNA from the patient with primer 67-27 (on exon 2) and 
primer  67-28  (on  intron  2)  and  directly  sequenced  this 
fragment with primer 67-30 (also on intron 2; see reference 
17).  Again, the AGA 170-172  or GAA  171-173  or AAG 
172-174 deletion was found, this time with the normal se- 
quence at equal intensity (data not shown; a schematic rep- 
resentation  is given in Fig. 2 A). Analysis of the other am- 
plified cDNA fragments from this patient revealed no other 
mutations.  However,  Southern  blot  analysis  of nonampli- 
fled  genomic  DNA  with  a  full-length  p67-phox  cDNA 
probe  after  treatment  with  restriction  enzyme  EcoRI 
showed a much weaker stained 5-kb band than in the con- 
trol  situation  (Fig.  2  C).  In addition,  after  treatment  with 
HindlII,  an  abnormal  extra  band  of ~13  kb  was  found 
(Fig. 2  /3). These results are compatibile with an  11-13-kb 
deletion in the NCF-2 gene. Thus, the patient seems to be 
a compound heterozygote for a 5SLys deletion and a larger 
deletion in p67-phox.  Family members of this patient were 
not available for study. 
Translocation of p47-phox  and p67-phox  in Intact Granulo- 
cytes.  Apparently,  the  p67-phox  with  the  predicted  in- 
frame deletion  of SSLys was expressed in the patient's  cells, 
because  a  band  of normal  size  was  detected  on  Western 
blot (Fig.  1).  The lower expression of the protein is abnor- 
mal: carriers of A67  ~ have (almost) normal amounts ofp67- 
phox  protein  in  their  neutrophil  cytosol  (unpublished  re- 
sults).  The product from the patient's  other allele with the 
large  deletion  was  not  expressed,  because  no  protein  of 
lower size was detected. To analyze the functional defect in 
this  patient,  we studied  the  translocation  of p67-phox  and 
p47-phox  in the granulocytes activated with PMA or STZ. 
As  shown  in  Fig.  3,  PMA  in  normal  cells  induced  a  fair 
translocation  of both p47-phox  and p67-phox,  and  STZ  (a 
more physiological stimulus) induced a mitigated transloca- 
tion,  probably caused by a less  stable assembly of NADPH 
oxidase.  However,  in  the  patient's  cells,  both  proteins 
failed to translocate  to the plasma membrane and were re- 
tained in the supernatant with both stimuli.  In granulocytes 
ofp67-phox-deficient  patients,  it has been found that p47- 
phox can translocate  on its  own  (30,  31).  Nevertheless,  we 
found <  1% interaction ofp47-phox with the plasma mem- A  Genomic 
Exon  2  Exon  3 
control  ....  u*-s  Ir  GCA  GAG  AAG[  gtga 8 ..... tcag  IGCC TTT  ... 
Exon  2  ]~  Exon  3 
patient  ....  u~,s  ICTCTC... C;CA GAG ] gt,,g....~t~.g  ]GCC TTT ... 
cDNA 
56  58  60 
control  ...  Ala  Glu  Lys  Ala  Phe  ... 
... GCA GAG AAG GCC TTT ... 
166  169  172  175  178 
t 
56 
natient  ... Ala  Glu  Ala  Phe  ... 
... GCA GAG GCC TTT ... 
Figure  2.  DNA analysis. (A) DNA sequence  of genomic  I)NA and 
eDNA of one of the patient's alleles compared with the control sequence. 
Uppercase letters indicate coding sequences and lowercase letters indicate 
intron sequences.  The  arrow  indicates  the  triplet  nucleotide  and  the 
amino acid present in the  control  sequence but missing in the  patient. 
Amino acid and nucleotide numbering is according to reference 16. The 
triplet  nucleotide  deleted  in the patient  may be AGA  170-172,  GAA 
171-173, or AAG 172-174.  (B and C) restriction fraglnent length poly- 
morphism analysis of genomic DNA from the patient and from control 
donors. The DNA was digested with Hindlll (B) or EcoRl (C') and elec- 
trophoresed in 1.2% (wt/voI) agarose. After Southern blotting,  the frag- 
ments were hybridized with a full-length p67-phox DNA probe labeled 
by random priming. 
brane of another p67-phox-deficient patient, both in PMA- 
activated granulocytes and in the cell-free system (J.  Leusen, 
unpublished results).  Also, in CGD  patients with a  nmta- 
tion in either the light or the heavy subunit of cytochrome 
bss  ~, we found virtually no translocation of either p47-phox 
or p67-phox (28, 32). 
Translocation of  p47-phox and p67-phox in the Cell-free Sys- 
tem.  In the  patient described  here,  the  lack  of transloca- 
tion  of both  cytosolic phox  proteins  could  be  the  conse- 
quence of a  disturbed binding of the mutated p67-phox to 
cytochrome  bss  8.  To  investigate  this  possibility, we  tested 
the translocation ofnmtated p67-phox as a fusion protein to 
GST in the  cell-free sytem.  As shown  in Fig.  4,  p47-phox 
and  p67-phox  translocate  to  the  plasma  membrane,  using 
either wild-type or mutated p67-phox.  The absence of trans- 
location  with  membranes  of  an  X-linked  CGD  patient 
shows the dependence of this translocation on the presence 
of cytochrome  bss  s.  However,  the membranes binding this 
mutated  p67-phox  did  not support  superoxide  production 
upon addition of NADPH  (see legend to Fig. 4). 
Analysis  of p21-racl  Binding  to  GST  Fusion Proteins. 
To explain the functional defect ofp67-phoxASSLys  causing 
CGD  in  this  patient,  we  studied  the  p21-racl  binding to 
p67-phox  in a  dot-blot  assay.  It  has  been  shown  that  the 
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cytes. Cells were stimulated with PMA (100 ng/ml) or STZ (1 mg/ml) 
for 7 rain and fractionated. Subsequently, supernatants and plasma mem- 
branes were immunoblotted as described in Fig. 1. 
Figure 4.  Translocation ofp47-phox and p67-phox in the cell-flee sys- 
tem. 1 p~g ofGST-p47-phox, 1 Ixg of GST-p67-phox, and a fraction con- 
taining p21-rac (obtained from 240 p~g of cytosolic protein) were mixed 
with plasma membranes (40 p~g). After activation with SDS and GTP'/S 
and centrifugation  over sucrose gradients, plasma membranes were  col- 
lected. One fiRh of the membrane fractions were assayed for superoxide 
production,  and the rest were  processed for Western blotting.  (Lanes 1 
and 3)  Recombinant p47-phox and p67-phox-wt with  normal or Xb  ° 
membranes (5.27 and 0.35); (lanes 2 and 4) recombinant p47-phox and 
p67-phoxASSLys with normal or Xb  ° membranes  (0.40 and 0.38). The 
rate of superoxide production of each membrane preparation is given be- 
tween brackets (in nmol/10 ttg of membrane protein per rain). 
small  GTPase  p21-rac1 can  specifically interact with  p67- 
phox  (20,  27),  the first  199  amino acids ofp67-phox  being 
important for  this  interaction.  As  shown  in  Fig.  5,  GTP- 
loaded  p21-rac1  bound  to  the  wild-type  GST-p67-phox 
but not to  the  58Lys-deleted form  of GST-p67-phox.  The 
presence  of  wild-type  and  mutated  p67-phox  was  con- 
firmed by immunostaining with an antibody directed against 
the COOH-terminus  ofp67-phox.  Under the same experi- 
mental conditions, binding of GTP-loaded p21-rac2 could 
not be detected in either the wild-type or mutated form of 
p67-phox  (data not shown). These results suggest that 5SLys 
ofp67-phox is in a putative binding site for p21-racl,  or, al- 
ternatively, is important for maintaining the NH 2 terminus 
in a proper conformation for p21-rac1 binding. 
For the past two years,  conflicting data have been pub- 
lished about the function of p21-rac proteins in the assem- 
bly ofNADPH  oxidase. It has been unclear whether or not 
p21-rac  becomes  stably  associated  with  the  plasma  mere- 
brane upon cell activation (33-35),  and whether transloca- 
tion  of p21-rac is  dependent  or  independent  of p47-phox 
and p67-phox  (36-40). The only aberration we observed in 
the neutrophils of this CGD  patient was the inability of its 
mutant p67-phox protein to interact with p21-rac1, whereas 
interaction  with  p21-rac2  (as  reported  by  Dorseuil  et  al. 
[41])  could  not be  demonstrated  even with  the  wild-type 
p67-phox.  Our  results  seem  therefore  to  corroborate  the 
results of Dusi et al.  (42), who reported  that the transloca- 
tion ofp21-racl,  but not that ofp21-rac2,  is dependent on 
the  presence  of p47-phox  and  p67-phox.  The  interaction 
between p21-racl  and p67-phox  may not  only be  manda- 
tory for proper NADPH  oxidase assembly (as indicated by 
the disturbed translocation of cytosolic  components in the 
neutrophils of this patient),  but also  for induction of cata- 
lytic activity: the mutated p67-phox  translocated in the cell- 
free system (i.e., under artificial conditions) did not support 
oxidase activity. 
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Figure 5.  Analysis  of p21-racl  binding to  GST 
fusion  proteins.  3  p,g  of  GST,  GST-p47-phox, 
GST-p67-phox,  or  GST-p67-phoxASSLys were 
spotted onto nitrocellulose (left lane). For compari- 
son, increasing amounts of GST-p67wt were spot- 
ted in the adjacent (right) lanes. The blot was then 
incubated  with  [32P]ctGTP-loaded p21-racl (left). 
Binding was visualized by subsequent exposure of 
the blot to film for 1 h. Afterward, the presence of 
p67-phox was verified by immunostaining  with an 
antibody against the COOH temainus of p67-phox 
visualized by enhanced chemiluminescence (right). We thank Dr. T. Leto (National Institutes of Health, Bethesda, MD) for providing the GST vector encoding 
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